ERBB2 and chronic myelogenous leukemia, BCR-ABL1 positive: Drugs such as the tyrosine kinase inhibitors (TKIs) developed against the BCR-ABL fusion product in chronic myeloid leukaemia (CML) and the receptor products of HER2 mutations in breast cancer have transformed the prognosis of these cancers (Druker et al., 2006).